9776 — Sapporo Clinical Laboratory Balance Sheet
0.000.00%
- ¥3bn
- ¥2bn
- ¥20bn
- 84
- 96
- 68
- 96
Annual balance sheet for Sapporo Clinical Laboratory, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 2,728 | 2,361 | 2,991 | 3,664 | 3,976 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,582 | 2,749 | 2,995 | 2,924 | 2,919 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 5,932 | 5,913 | 7,230 | 7,311 | 7,697 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4,865 | 7,758 | 8,128 | 8,449 | 8,191 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 11,553 | 14,511 | 16,149 | 16,521 | 16,681 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,796 | 3,106 | 3,282 | 3,257 | 3,307 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,090 | 5,239 | 6,035 | 5,936 | 5,744 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 8,463 | 9,272 | 10,114 | 10,585 | 10,937 |
Total Liabilities & Shareholders' Equity | 11,553 | 14,511 | 16,149 | 16,521 | 16,681 |
Total Common Shares Outstanding |